Published • loading... • Updated
Study: Cancer Jab Eliminates Tumors in Patients
Researchers said the injection erased tumours in 15 patients and helped 42% of trial participants, offering a new option after chemotherapy and immunotherapy failed.
- On Sunday, researchers will present results at the American Society of Clinical Oncology meeting in Chicago showing amivantamab shrank or eradicated head and neck tumours in 43 of 102 patients, including 15 complete responses.
- This triple-action jab blocks EGFR and MET pathways while activating the immune system, targeting HPV-negative head and neck cancers that typically resist standard chemotherapy and immunotherapy.
- Carl Walsh joined the OrigAMI-4 trial at the Royal Marsden in July 2025, reporting his diet and speech returned to normal; most patients experienced mild side-effects, with fewer than one in 10 stopping treatment.
- Describing the responses as 'unprecedented,' Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, noted this represents a significant step forward for thousands of patients annually.
- Johnson is evaluating amivantamab in about 60 clinical trials across multiple cancer types, with similar results reported in lung cancer, signaling potential to extend beyond current head and neck applications.
Insights by Ground AI
42 Articles
42 Articles
Doctors praised the "unprecedented" results of a clinical trial in 11 countries demonstrating that a triple injection against cancer can eradicate whole tumours in patients.
·Portugal
Read Full Article
Malay MailReposted by 
AlKhaleej Today
AlKhaleej TodayDoctors report breakthrough as cancer jab reportedly eradicates tumours in international trial across 11 countries
LONDON, May 31 — Doctors have reported striking results from an international trial of a triple action cancer jab that eliminated tumours in some patients.According to The Guardian, the drug, known as amivantamab, was tested across 11 countries on patients whose cancers had spread or returned and no longer responded to standard therapies.“These are unprecedentedly strong responses in patients whose disease has become resistant to both chemothera…
·Selangor, Malaysia
Read Full ArticleCoverage Details
Total News Sources42
Leaning Left7Leaning Right9Center7Last UpdatedBias Distribution39% Right
Bias Distribution
- 39% of the sources lean Right
39% Right
L 31%
C 30%
R 39%
Factuality
To view factuality data please Upgrade to Premium
